Cross-Sector entity
All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention AtriCure, the most common co-covered peer. We currently track 1 Cross-Sector story that mention SPDR S&P Biotech ETF, all published on March 22, 2026.
1 verified story tracked
Last mentioned: Mar 22, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention AtriCure, the most common co-covered peer. We currently track 1 Cross-Sector story that mention SPDR S&P Biotech ETF, all published on March 22, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering SPDR S&P Biotech ETF. Shared-story counts are live from our verified record — not editorial picks.
DAFNA Capital Management reduced its position in Axogen by approximately $6.5 million during the fourth quarter of 2025, a move that follows a significant 71% surge in the company's stock price. Despite the trim, Axogen remains a significant holding for the fund as the company continues to see 20% revenue growth driven by its peripheral nerve repair portfolio.
